Scarica l'app Stockscreener
4.555
2.57%
-0.115
Precedente Chiudi:
$4.67
Aprire:
$4.64
Volume 24 ore:
1.06M
Relative Volume:
0.37
Capitalizzazione di mercato:
$1.25B
Reddito:
$6.31M
Utile/perdita netta:
$-99.93M
Rapporto P/E:
-12.85
EPS:
-0.3544
Flusso di cassa netto:
$-85.14M
1 W Prestazione:
-5.01%
1M Prestazione:
-3.60%
6M Prestazione:
+53.72%
1 anno Prestazione:
+180.86%
Intervallo 1D:
$4.47
$4.67
Intervallo di 1 settimana:
$4.47
$5.07
Portata 52W:
$1.05
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Nome
Taysha Gene Therapies Inc
Settore
Industria
Telefono
(214) 612-0000
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.56 | 1.28B | 6.31M | -99.93M | -85.14M | -0.3544 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.56 | 122.71B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.85 | 82.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
765.93 | 50.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.64 | 43.42B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
318.65 | 38.98B | 4.98B | 69.60M | 525.67M | 0.5198 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Raymond James | Strong Buy |
| 2025-07-11 | Iniziato | BofA Securities | Buy |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-04-09 | Iniziato | Piper Sandler | Overweight |
| 2023-02-01 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-03-09 | Iniziato | Robert W. Baird | Outperform |
| 2022-03-01 | Iniziato | Wells Fargo | Overweight |
| 2022-02-18 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | Guggenheim | Buy |
| 2021-07-16 | Iniziato | Needham | Buy |
| 2021-06-24 | Iniziato | Truist | Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-06-09 | Iniziato | Wedbush | Outperform |
| 2021-06-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Ripresa | Jefferies | Buy |
| 2021-02-24 | Iniziato | William Blair | Outperform |
| 2021-01-05 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-19 | Iniziato | Goldman | Buy |
| 2020-10-19 | Iniziato | Jefferies | Buy |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
What is the next catalyst for Taysha Gene Therapies Inc.Long Setup & Precise Buy Zone Identification - mfd.ru
Will Taysha Gene Therapies Inc. benefit from AI trendsTrade Entry Summary & Detailed Earnings Play Alerts - mfd.ru
How liquid is Taysha Gene Therapies Inc. stock2025 Breakouts & Breakdowns & Technical Pattern Alert System - mfd.ru
RTW INVESTMENTS, LP Reduces Stake in Taysha Gene Therapies Inc - GuruFocus
CEO Moves: How cyclical is Taysha Gene Therapies Incs revenue stream2025 Winners & Losers & Community Verified Trade Alerts - baoquankhu1.vn
GSA Capital Partners LLP Increases Holdings in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies (TSHA) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Rate Cut: What is the next catalyst for Taysha Gene Therapies IncEntry Point & Growth Oriented Trade Recommendations - baoquankhu1.vn
Commit To Buy Taysha Gene Therapies At $2.50, Earn 16.8% Annualized Using Options - Nasdaq
Portfolio Recap: How does NBBK perform in inflationary periodsJuly 2025 Chart Watch & Consistent Return Investment Signals - baoquankhu1.vn
Taysha Gene Therapies, Inc. (TSHA) Investor Outlook: Analyst Consensus Reveals 136.56% Potential Upside - DirectorsTalk Interviews
Does Taysha Gene Therapies Inc. have declining or rising EPSQuarterly Earnings Summary & Fast Entry Momentum Alerts - mfd.ru
Here’s what analysts are saying about Taysha Gene Therapies (TSHA) - MSN
Can Taysha Gene Therapies Inc. outperform under higher oil pricesGDP Growth & Weekly Return Optimization Plans - mfd.ru
Taysha Gene Therapies, Inc. $TSHA Holdings Trimmed by Tybourne Capital Management HK Ltd. - MarketBeat
Is Taysha Gene Therapies Inc undervalued by DCF analysisJuly 2025 Outlook & Fast Moving Stock Trade Plans - baoquankhu1.vn
Retail Trends: What is the next catalyst for Taysha Gene Therapies IncPortfolio Gains Summary & High Accuracy Buy Signal Tips - baoquankhu1.vn
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies (TSHA) Awards Restricted Stock Units to Ne - GuruFocus
Did Rett Trial Milestones Just Shift Taysha Gene Therapies' (TSHA) Gene Therapy Approval Path Narrative? - Yahoo Finance
Taysha Gene Therapies, Inc. (TSHA) gains Wells Fargo’s support on Rett syndrome program progress - MSN
Taysha’s REVEAL Trial Progress Puts Rett Gene Therapy And Valuation In Focus - Sahm
Cell And Gene Therapy Enters ‘Disciplined Growth Cycle’ As Commercial Momentum Builds - Citeline News & Insights
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo’s Support on Rett Syndrome Program Progress - Insider Monkey
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress - Finviz
Institution Moves: Does Taysha Gene Therapies Inc have strong fundamentals2025 Retail Activity & Stepwise Swing Trade Plans - baoquankhu1.vn
Taysha Gene Therapies, Inc. $TSHA Shares Sold by SG Americas Securities LLC - MarketBeat
Activity Recap: How cyclical is Taysha Gene Therapies Incs revenue streamWeekly Stock Report & Precise Trade Entry Recommendations - baoquankhu1.vn
Pivotal Trial for Taysha's Rett Syndrome Gene Therapy TSHA-102 Doses First Patient - CGTLive®
Taysha Doses First Patient in Pivotal Trial for Rett Syndrome Gene Therapy TSHA-102, Aligns With FDA on BLA Plans - NeurologyLive
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
10 Best Strong Buy Stocks to Invest In Under $5 - Insider Monkey
Here’s What Analysts Are Saying About Taysha Gene Therapies (TSHA) - Insider Monkey
Taysha Gene Therapies (NASDAQ:TSHA) CEO Sells $649,747.75 in Stock - MarketBeat
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) CEO Sells 41,312 Shares of Stock - MarketBeat
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 26,918 Shares of Stock - MarketBeat
Kamran Alam Sells 78,968 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock - MarketBeat
Kamran Alam Sells 23,849 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock - MarketBeat
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.2%What's Next? - MarketBeat
Taysha Gene Therapies commences underwritten public offering - MSN
Dip Buying: How liquid is Taysha Gene Therapies Inc stock2025 Support & Resistance & Entry Point Strategy Guides - baoquankhu1.vn
Trading Recap: Can PBYI generate free cash flowJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
VIX Spike: Is Taysha Gene Therapies Inc stock good for income investors2025 Sector Review & Technical Entry and Exit Tips - baoquankhu1.vn
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 200,000 Shares of Stock - MarketBeat
Nagendran sells Taysha gene therapies (TSHA) stock for $942k By Investing.com - Investing.com Canada
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects - Insider Monkey
10 Best Penny Stocks to Buy for 2026 - Insider Monkey
Buybacks Report: What is KIDSs TAM Total Addressable MarketIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.3%Should You Sell? - MarketBeat
Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.66%
0.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):